To investigate the effects of Tongxinluo Capsules combined with betaloc on cardiac function in patients with stable angina pectoris of coronary heart disease.Methods:A total of 84 patients with stable angina pectoris of coronary heart disease admitted to Hebei Yiling Hospital from January 2018 to January 2020 were selected as research objects.According to random number table method，they were divided into a control group and an observation group，with 42 cases in each group.The control group was given Betaloc on the basis of conventional treatment.The observation group was given Tongxinluo Capsules treatment on the basis of the treatment of the control group.The efficacy，TCM symptom score，echocardiographic index［left ventricular ejection fraction(LVEF)，left ventricular end diastolic diameter(LVEDD)，left ventricular end systolic diameter(LVESD)］，blood lipid index［total cholesterol(TC)，triglycerides(TG)，low-density lipoprotein cholesterol(LDL-C)，high-density lipoprotein cholesterol(HDL-C)］，angina pectoris，adverse reactions were compared.Results:The treatment effect of the observation group was better than that of the control group(P<0.05).After treatment，the TCM symptom scores，LVEDD，LVESD，TG，TC，LDL-C，angina pectoris frequency，duration of attacks of the two groups all decreased，and LVEF and HDL-C increased.The TCM syndrome score，LVEDD，LVESD，TG，TC，LDL-C，angina pectoris frequency and duration of attacks of the observation group were lower than those of the control group，while LVEF and HDL-C were higher than those of the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion:Tongxinluo Capsules combined with Betaloc in the treatment of patients with stable angina pectoris of coronary heart disease can improve clinical efficacy，improve heart function，reduce blood lipid levels and the onset of angina pectoris，and has good safety.